Otsuka Holdings Co., Ltd. (OTSKF)
| Previous close | 0.00 |
| Open | 45.73 |
| Bid | 53.67 x 40000 |
| Ask | 58.66 x 40000 |
| Day's range | 45.73 - 45.73 |
| 52-week range | 35.91 - 45.73 |
| Volume | |
| Avg. volume | 182 |
| Market cap | 29.902B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 24.99 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (2.02%) |
| Ex-dividend date | 27 Dec 2024 |
| 1y target est | N/A |
- Zacks
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
- Zacks
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
- Reuters
US FDA approves Otsuka's blood pressure treatment device for use
The U.S. Food and Drug Administration (FDA) approved the use of a device made by an Otsuka Holdings unit in a type of surgery to treat high blood pressure, the company said on Wednesday. The approval for Paradise Ultrasound Renal Denervation comes after an FDA panel backed its use. The device is made by Japanese company Otsuka's unit ReCor and is indicated for use in patients whose hypertension, or high blood pressure, cannot be controlled with drugs.
